Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 347

Similar articles for PubMed (Select 14500371)

1.

Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients.

Koukourakis MI, Giatromanolaki A, Brekken RA, Sivridis E, Gatter KC, Harris AL, Sage EH.

Cancer Res. 2003 Sep 1;63(17):5376-80.

2.

Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer.

Giatromanolaki A, Koukourakis MI, Sivridis E, Pastorek J, Wykoff CC, Gatter KC, Harris AL.

Cancer Res. 2001 Nov 1;61(21):7992-8.

3.

Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival.

Giatromanolaki A, Koukourakis MI, Sivridis E, Turley H, Talks K, Pezzella F, Gatter KC, Harris AL.

Br J Cancer. 2001 Sep 14;85(6):881-90.

4.

Different patterns of stromal and cancer cell thymidine phosphorylase reactivity in non-small-cell lung cancer: impact on tumour neoangiogenesis and survival.

Koukourakis MI, Giatromanolaki A, Kakolyris S, O'Byrne KJ, Apostolikas N, Skarlatos J, Gatter KC, Harris AL.

Br J Cancer. 1998 May;77(10):1696-703.

5.

DEC1 (STRA13) protein expression relates to hypoxia- inducible factor 1-alpha and carbonic anhydrase-9 overexpression in non-small cell lung cancer.

Giatromanolaki A, Koukourakis MI, Sivridis E, Turley H, Wykoff CC, Gatter KC, Harris AL.

J Pathol. 2003 Jun;200(2):222-8.

PMID:
12754744
6.

Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer.

Swinson DE, Jones JL, Richardson D, Wykoff C, Turley H, Pastorek J, Taub N, Harris AL, O'Byrne KJ.

J Clin Oncol. 2003 Feb 1;21(3):473-82.

PMID:
12560438
7.

An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers.

Le QT, Chen E, Salim A, Cao H, Kong CS, Whyte R, Donington J, Cannon W, Wakelee H, Tibshirani R, Mitchell JD, Richardson D, O'Byrne KJ, Koong AC, Giaccia AJ.

Clin Cancer Res. 2006 Mar 1;12(5):1507-14.

8.

Assessment of vascular maturation in non-small cell lung cancer using a novel basement membrane component, LH39: correlation with p53 and angiogenic factor expression.

Kakolyris S, Giatromanolaki A, Koukourakis M, Leigh IM, Georgoulias V, Kanavaros P, Sivridis E, Gatter KC, Harris AL.

Cancer Res. 1999 Nov 1;59(21):5602-7.

9.

Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis.

Koukourakis MI, Giatromanolaki A, Sivridis E, Bougioukas G, Didilis V, Gatter KC, Harris AL; Tumour and Angiogenesis Research Group.

Br J Cancer. 2003 Sep 1;89(5):877-85.

10.

Quantitative analysis of carbonic anhydrase IX mRNA in human non-small cell lung cancer.

Simi L, Venturini G, Malentacchi F, Gelmini S, Andreani M, Janni A, Pastorekova S, Supuran CT, Pazzagli M, Orlando C.

Lung Cancer. 2006 Apr;52(1):59-66. Epub 2006 Feb 28.

PMID:
16513206
11.

Platelet-derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in non-small-cell lung cancer.

Koukourakis MI, Giatromanolaki A, O'Byrne KJ, Comley M, Whitehouse RM, Talbot DC, Gatter KC, Harris AL.

Br J Cancer. 1997;75(4):477-81.

12.
13.

Prognostic impact of fibroblast growth factor 2 in non-small cell lung cancer: coexpression with VEGFR-3 and PDGF-B predicts poor survival.

Donnem T, Al-Shibli K, Al-Saad S, Busund LT, Bremnes RM.

J Thorac Oncol. 2009 May;4(5):578-85. doi: 10.1097/JTO.0b013e31819f2e38.

PMID:
19318994
14.

Wnt5a expression is associated with the tumor proliferation and the stromal vascular endothelial growth factor--an expression in non-small-cell lung cancer.

Huang CL, Liu D, Nakano J, Ishikawa S, Kontani K, Yokomise H, Ueno M.

J Clin Oncol. 2005 Dec 1;23(34):8765-73.

15.

Hepatoma-derived growth factor as a prognostic marker in completely resected non-small-cell lung cancer.

Iwasaki T, Nakagawa K, Nakamura H, Takada Y, Matsui K, Kawahara K.

Oncol Rep. 2005 Jun;13(6):1075-80.

PMID:
15870924
16.

Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) levels, as prognostic indicators in NSCLC.

Iwasaki A, Kuwahara M, Yoshinaga Y, Shirakusa T.

Eur J Cardiothorac Surg. 2004 Mar;25(3):443-8.

PMID:
15019676
17.

Prognostic impact of platelet-derived growth factors in non-small cell lung cancer tumor and stromal cells.

Donnem T, Al-Saad S, Al-Shibli K, Andersen S, Busund LT, Bremnes RM.

J Thorac Oncol. 2008 Sep;3(9):963-70. doi: 10.1097/JTO.0b013e3181834f52.

PMID:
18758297
18.
19.

Matrix metalloproteinase-2 status in stromal fibroblasts, not in tumor cells, is a significant prognostic factor in non-small-cell lung cancer.

Ishikawa S, Takenaka K, Yanagihara K, Miyahara R, Kawano Y, Otake Y, Hasegawa S, Wada H, Tanaka F.

Clin Cancer Res. 2004 Oct 1;10(19):6579-85.

20.

Prognostic value of hyaluronan expression in non-small-cell lung cancer: Increased stromal expression indicates unfavorable outcome in patients with adenocarcinoma.

Pirinen R, Tammi R, Tammi M, Hirvikoski P, Parkkinen JJ, Johansson R, Böhm J, Hollmén S, Kosma VM.

Int J Cancer. 2001 Jan 20;95(1):12-7.

PMID:
11241304
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk